



Amgen By Your Side

is a support program for patients prescribed
ACTIMMUNE® (interferon gamma-1b)

Our dedicated team is your patient's partner, committed to providing nonmedical support to help patients as they start and continue on treatment as you prescribe.



Patient Support



Financial Assistance



**Insurance Benefits
Investigation**



**Initiate your patient's enrollment in Amgen By Your Side by
submitting the Patient Enrollment Form.**

OPTIONS AVAILABLE AT:



amgenbyyourside.com/actimmune/hcp



ACTIMMUNE®
(Interferon gamma-1b)

Our mission is to connect, coordinate, and champion your patient at the most important steps along the way:



Connect

Your patient will be connected to one person dedicated to partnering with them throughout their treatment experience



Coordinate

Your patient will receive educational support on insurance, financial assistance options, important appointment-related information, and more



Champion

Your patient's dedicated partner will empower them to be confident self-advocates for maintaining treatment goals

When you are ready to prescribe:

Simplify access to treatment for your patients

The Amgen By Your Side team is here to assist your patients every step of the way

Amgen By Your Side offers a wide range of patient-focused services:



Patient Support

- Provide dedicated, one-on-one support for your patients
- Work directly with individual patients to answer nonmedical, logistical questions and provide support upon enrollment



Insurance Benefits Investigation

- Provide education to you and your staff about product coding and billing
- Educate you and your staff about insurance processes, including specific payor requirements and examples



Financial Assistance

- Educate patients on the results of their benefits investigation and review their insurance coverage
- Help patients understand potential out-of-pocket costs and financial assistance options

Meet the Amgen By Your Side team

Initiate your patient's enrollment in Amgen By Your Side by submitting the Patient Enrollment Form at amgenbyyourside.com/actimmune/hcp. Your patient must complete enrollment to access our patient-focused services and resources.



Clinical Nurse Educator (CNE)

The CNE provides dedicated, one-on-one support for your patient.

- They work directly with individual patients to answer nonmedical, logistical questions and provide support upon enrollment
- Additionally, the CNE educates about navigating insurance processes and accessing treatment on your patient's behalf
- The CNE has the expertise and tools to support the patient by educating on patient benefits, prior authorization requirements, payor policies, and coding and claim submissions



Case Manager

Case Managers work on behalf of the patient and interact with the doctor's office to ensure insurance information is accurate and to inform the office on insurance criteria for the submission of a prior authorization. These comprehensive services are free of charge to your patient.

In addition, a Case Manager:

- May reach out to the doctor's office after a prescriber initiates enrollment and inquire about missing information on the enrollment form
- Has the expertise and knowledge to educate the doctor's office on payor policies and insurance criteria for access to Amgen products

The team at Amgen By Your Side is available by phone at 1-877-305-7704

We believe patients should pay the lowest amount possible

Patients with commercial insurance may be eligible for a \$0 co-pay for medication through our Amgen Commercial Co-Pay Program.*



CNEs can speak with patients prescribed ACTIMMUNE about the insurance approval process and help them understand coverage options

*The Amgen Commercial Co-Pay Program may be available to patients who meet the following minimum criteria:

- Patient's prescription cannot be paid in part or in full by any government-funded program including but not limited to: Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, Department of Defense (DOD), TRICARE, or any state, patient foundation, or other pharmaceutical program.
- Patient is prescribed a covered Amgen rare disease medication for an indication approved by the Food and Drug Administration; the indication for each product is shown in its prescribing information.
- Patient is a resident of the United States.
- Patient must be commercially insured and have financial responsibility for a portion of the drug and/or infusion cost if applicable.

The assistance offered under this co-pay program is subject to additional terms and conditions, including but not limited to the following:

Terms and Conditions: Offer cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription. Not valid for prescriptions reimbursed in whole or in part by any government-funded program including but not limited to: Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE, or any state, patient foundation, or other pharmaceutical program. Offer good only in the United States at participating specialty pharmacies or sites of care. Offer not valid where otherwise prohibited by law, for example by applicable state law prohibiting co-pay cards. Amgen reserves the right to rescind, revoke, or amend offer without notice. The selling, purchasing, trading, or counterfeiting of any co-pay card or benefits is prohibited by law. This co-pay program is not insurance and is not intended to substitute for insurance.

Participating Pharmacies or Healthcare Providers: By using this co-pay program, you acknowledge and confirm that the prescription will not be reimbursed in whole or in part by any government-funded program (such as, without limitation, Medicare, Medicaid, VA, DOD, TRICARE) and the patient and prescription meet the eligibility criteria set forth in the terms and conditions. You are responsible for reporting the receipt of the co-pay program benefits as required by an insurer, payor, or applicable law or regulation.

Patients: By enrolling in this co-pay program, you acknowledge and confirm that you and the prescription meet the eligibility requirements set forth in the terms and conditions, including that the prescription will not be reimbursed in whole or in part by any government-funded program (such as, without limitation, Medicare, Medicaid, VA, DOD, TRICARE). You may not seek any claims to government payors or other payors or insurers for this prescription. You may not seek reimbursement from any health savings, flexible savings, or other healthcare reimbursement account for any amounts received from the co-pay program. You are responsible for reporting the receipt of the co-pay program benefits as required by an insurer, payor, or applicable law or regulation.



Simplify access to ACTIMMUNE for your patients with Amgen By Your Side

Initiate your patient's enrollment in Amgen By Your Side by submitting the Patient Enrollment Form.

Options available at: amgenbyside.com/actimmune/hcp



Questions?

Contact the Amgen By Your Side team

Phone:

1-877-305-7704



ACTIMMUNE[®]
(Interferon gamma-1b)

Please see Indications and Important Safety Information on page 8 and [Full Prescribing Information](#).



INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

- For reducing the frequency and severity of serious infections associated with chronic granulomatous disease
- For delaying time to disease progression in patients with severe, malignant osteopetrosis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- In patients who develop or have known hypersensitivity to interferon gamma-1b, *E. coli*-derived products, or any component of the product

WARNINGS AND PRECAUTIONS

- ACTIMMUNE should be used with caution in patients with:
 - ◊ Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
 - ◊ Seizure disorders or compromised central nervous system function
 - ◊ Myelosuppression or receiving other potentially myelosuppressive agents
 - ◊ Severe renal insufficiency
 - ◊ Age <1 year
- Monitoring:
 - ◊ Before starting ACTIMMUNE and every 3 months during treatment, hematologic tests, blood chemistries, and urinalysis are recommended for all patients
 - ◊ Patients begun on ACTIMMUNE before the age of 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
 - ◊ Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE

USE IN SPECIFIC POPULATIONS

- ACTIMMUNE should be used during pregnancy only if the potential benefit to the patient outweighs the potential risk to the fetus
- It is not known if ACTIMMUNE is excreted in human milk, so either ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the patient
- In younger patients, long-term effects of ACTIMMUNE on fertility are not known
- In animal studies, both male and female fertility was negatively impacted by doses significantly higher than the maximum clinical dose

DRUG INTERACTIONS

- Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
- Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

- The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
- Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
- Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
- At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness

Please see [Full Prescribing Information](#) for complete safety information.